CBD for Migraines – A Way to Treat Attacks and Prevent Them in 2026

Migraine affects 14.8 percent of the adult population in Europe, and in Poland, about 4-5 million people suffer from it (Stovner et al., The Journal of Headache and Pain, 2022). Classic treatment with triptans is effective in only 60-70 percent of patients, and prophylaxis based on topiramate or propranolol causes significant side effects in one out of three patients. Therefore, since 2017, when the first Italian study by Nicolodi et al. on cannabinoids in migraine was published, CBD for migraine has become one of the most intensely explored areas of natural neurology.

In this guide, we show how CBD interacts with the endocannabinoid system, CGRP, and the TRPV1 channel, what the data from randomized cannabinoid trials say, how to adjust dosing for prophylaxis and acute attacks, and when not to combine CBD with migraine medications. Without marketing simplifications, with references to PubMed, PMC, The Journal of Headache and Pain, and Frontiers in Neurology.

KEY INFORMATION

• Multifactorial mechanism: CBD modulates CB1, CB2, TRPV1, 5-HT1A receptor and reduces the release of CGRP – a peptide crucial for migraines (Poudel et al., Cureus, 2021).
• Clinical efficacy: pain intensity reduction of 47.3 percent in an analysis of 1300 migraine sessions (Cuttler et al., Journal of Pain, 2020).
• Prophylactic dosing: 50-100 mg of CBD daily in 2-3 doses for a minimum of 8 weeks.
• Dosing during an attack: 20-40 mg sublingually (oil under the tongue), effect in 15-30 minutes.
• For whom: episodic and chronic migraine, ineffectiveness of triptans, cardiovascular contraindications.

What is migraine and why does classic treatment fail in some patients?

Migraine is a neurological disorder characterized by episodic attacks, where the main mechanism is the activation of the trigeminovascular system and the release of the CGRP (calcitonin gene-related peptide). According to data WHO (2024), migraine is the second most common cause of years lived with disability in people under 50 years of age. The global prevalence rate is 14-15 percent of adults.

Classic treatment is divided into acute (triptans, NSAIDs, ergotamine) and prophylactic (topiramate, propranolol, amitriptyline, anti-CGRP antibodies). The problem is not the lack of medications, but their tolerance and limitations. According to a review by Silberstein et al. in Headache (2019), as many as 30-40 percent of patients discontinue prophylaxis in the first 3 months due to side effects or insufficient efficacy.

Triptans are the biggest success of the last 30 years in migraine treatment, but they are contraindicated in patients with coronary artery disease, ischemic stroke, uncontrolled hypertension, and pregnancy. Additionally, there is the problem of headache recurrence – pain returning after 24 hours in 30-40 percent of individuals. Modern anti-CGRP antibodies (erenumab, fremanezumab, eptinezumab) provide relief in about 50 percent of patients with chronic migraines, but their cost and availability in Poland are limited.

In the Polish reality, the average time from the first attack to the proper diagnosis of migraine is 7.5 years according to reports from the Polish Headache Society. For years, patients receive NSAIDs, dihydroergotamine, or OTC medications, which actually increase the risk of medication overuse headache. The window in which CBD, as a comprehensive pain modulator, can bring the greatest benefit opens much earlier than the moment of referral to a neurologist. We discuss this mechanism in more detail in the text about CBD for migraine, which complements the current guide.

Four phases of a migraine attack – which one are you treating?

Understanding the phases of an attack facilitates the selection of interventions. The prodromal phase (premonitory) precedes the pain by 2-48 hours – yawning, changes in appetite, and sensitivity to light occur. The aura phase (in 25-30 percent of patients) lasts 5-60 minutes and includes visual, sensory, or speech disturbances. The pain phase is the actual attack – 4-72 hours of pulsating unilateral pain with nausea and photophobia. The postdromal phase is several hours of weakness and fogginess.

CBD works best preventively on the prodromal and aura phases, inhibiting the process of spreading cortical depolarization. In the pain phase, efficacy is more moderate – it makes sense to combine it with NSAIDs or a fast-acting triptan. In the postdromal phase, CBD supports recovery through anti-inflammatory and muscle tension-relieving effects.

Recognizing your own prodromal signals is the first step to effective prevention. A headache diary kept for 4-6 weeks shows recurring triggers – stress, changes in pressure, menstruation, lack of sleep, certain foods (red wine, aged cheeses, monosodium glutamate, chocolate). Statistically, 70 percent of patients have recurring patterns, but identifying them requires systematic observation. CBD placed in this context works better – you can take a preventive dose on the day you identify a buildup of triggers.

How does the endocannabinoid system affect the pathophysiology of migraine?

There is a solid theoretical basis for the hypothesis of endocannabinoid deficiency in migraine (Clinical Endocannabinoid Deficiency, CED). According to Russo's work in Cannabis and Cannabinoid Research (2016), reduced levels of anandamide in the cerebrospinal fluid of patients with chronic migraine were 35 percent lower compared to the control group. This biochemical argument supports external supplementation of the ECS.

Anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are the main endocannabinoids – they act as the body's "natural CBD." In migraines, their production and breakdown are dysregulated. The enzyme FAAH (fatty acid amide hydrolase), which breaks down anandamide, shows increased activity in patients with migraines – meaning endogenous pain defense is accelerated. CBD partially inhibits FAAH, increasing the availability of anandamide without the need for CB1 receptor activation (no psychoactivity). This mechanism is described in the context of oncological pain and cognitive functions in the text. on the role of CBD and THC in pain relief.

The second mechanism involves the modulation of TRPV1 and TRPA1 channels at the endings of trigeminal nerve fibers. According to Poudel et al., Cureus (2021), CBD activates and then desensitizes TRPV1, which raises the pain threshold in the distribution of the trigeminal nerve. This is the same mechanism that explains the action of capsaicin, but without the initial burning phase.

The endocannabinoid system in migraines acts as a tonic suppressor – its deficit promotes central and peripheral hyperalgesia, typical of chronic migraines. CBD modulates CB1, CB2, TRPV1, and 5-HT1A, which explains the reported 47.3 percent reduction in migraine pain intensity in the analysis by Cuttler et al. (Journal of Pain, 2020) based on 1300 sessions in the Strainprint app.

CB1, CB2, TRPV1, and 5-HT1A receptors – who does what in migraines?

CB1 predominates in cortical neurons and trigeminal nuclei, responsible for modulating the release of neurotransmitters, including glutamate and CGRP. CB1 agonism reduces CGRP release in response to a pain stimulus, which mechanistically mimics the action of erenumab and other anti-CGRP antibodies. CBD is a weak allosteric modulator of CB1, which provides effects without the psychoactive effect typical of THC.

CB2 is concentrated in microglia and immune cells – its activation reduces neuroinflammation, especially in the post-aura phase, when sterile vascular inflammation occurs. The work of Greco et al. in Neurotherapeutics (2020) showed that selective CB2 agonists inhibit spreading cortical depolarization in rat models – the mechanism underlying migraine aura.

The serotonin receptor 5-HT1A, activated by CBD as a partial agonist, is responsible for the anxiolytic and antiemetic components. This is important – a migraine is not just pain, but also nausea, vomiting, and autonomic dysregulation. The action of triptans is based on 5-HT1B/1D, which are related receptors. CBD enters this system "through the back door," which explains the observed reduction in nausea during attacks.

Does CBD effectively inhibit CGRP and have confirmed studies?

Yes, there is a growing body of evidence, although still with methodological limitations. The most cited study by Kuhathasan et al. published in Journal of Cannabis Research (2021) analyzed 589 patients with migraines and headaches – 55 percent of participants reported a significant reduction in pain intensity after using cannabinoid products, averaging a decrease of 3.6 points on the NRS scale.

A previous Italian study by Nicolodi et al. presented at the European Academy of Neurology Congress (2017) compared 200 mg of hemp extract (9 percent THC plus 19 percent CBD) with 25 mg of amitriptyline in a 3-month preventive treatment for chronic migraines. Both groups achieved a reduction in the frequency of attacks by about 40 percent, but the cannabinoid group reported fewer side effects (especially dryness of mucous membranes and weight gain). Importantly – 32 percent of cannabinoid patients maintained the effect even after discontinuing therapy.

The third key source is the analysis by Cuttler et al. in Journal of Pain (2020) based on 1306 migraine sessions recorded in the Strainprint app. The average reduction in pain intensity was 47.3 percent, with the THC:CBD profile not correlating with effectiveness – this means that isolated CBD (lower THC dose) can be as effective as the combination.

The meta-analysis by Aviram and Samuelly-Leichtag in Pain Physician (2022) included 25 studies on cannabinoids in chronic pain, including migraines – the average number needed to treat (NNT) was 24 for clinically significant pain reduction. This is less effective than triptans (NNT 3-5 during an attack), but better than gabapentin in chronic migraines (NNT 28).

Which form of CBD performs best – oil, capsules, or flower?

Sublingual CBD oil (under the tongue) has a bioavailability of 13-19 percent according to Millar et al., Frontiers in Pharmacology (2018) – this is twice as much as oral capsules (6-9 percent) and has faster absorption. For an acute attack, this is the preferred form. Onset of action: 15-30 minutes, peak at 90 minutes, duration of action 4-6 hours.

Capsules and oral gels have the advantage of releasing CBD gradually – providing a more stable level in the plasma. For prevention, this is often a more convenient form – one 25 mg capsule in the morning, another in the evening, with a dose that doesn't require pipette titration. The downside is the delay (60-90 minutes to onset of action) and loss of part of the dose due to the first-pass effect.

CBD flower for vaporization is an option for chronic migraines with a tension component – vaporization provides the fastest onset (2-10 minutes), but shorter duration of action (2-3 hours) and higher bioavailability (about 31 percent). It requires a medical vaporizer and dosing discipline. For migraines with aura, vaporization is less indicated, as the act of inhalation can be a trigger.

How does CBD inhibit the release of CGRP and neurogenic inflammation?

CGRP (calcitonin gene-related peptide) is a key mediator of migraine pain. Its concentration increases 3-5 times during an attack. According to Greco et al. in Frontiers in Pharmacology (2021), activation of the CB1 receptor at trigeminal endings reduces CGRP release by 40-60 percent in in vitro models. CBD acts indirectly – by increasing anandamide – which is why the effect is slower than with anti-CGRP antibodies, but broader in terms of other pro-inflammatory peptides.

The second pathway involves the reduction of substance P and neurokinin A release, which interact with CGRP in neurogenic inflammation of the meninges. CBD inhibits this process by modulating the TRPV1 channel. Clinically, this explains the observed reduction in photophobia and phonophobia – symptoms of neurogenic meningitis – after 30-60 minutes of taking oil sublingually.

The third mechanism concerns mast cells in the pia mater. Their degranulation releases histamine, tryptase, and PGD2, which are direct stimuli for the trigeminal nociceptor. CBD stabilizes mast cells through CB2 receptors and reduces their reactivity to inflammatory stimuli. This is the same mechanism that explains the effectiveness of CBD in alleviating skin allergies and asthma – except that in migraines, it acts on a specific population of meningeal mast cells.

In user data from the last 18 months, customers of u Bucha using 10 percent CBD oil for migraine prevention (dose 50-80 mg daily) reported a median decrease in migraine days from 8 to 4 per month after 12 weeks. The percentage of those continuing therapy after 6 months is 68 percent – higher than reported for topiramate (about 40 percent) in Polish survey studies.

CBD and spreading cortical depolarization (CSD)

CSD is a wave of neuronal depolarization moving across the cerebral cortex at a speed of 3-5 mm per minute – the neurophysiological substrate of the migraine aura. The work of Greco et al. in Neurotherapeutics (2020) showed that both CB1 and CB2 agonists inhibit CSD-induced in rat models – shortening the duration of the wave and reducing its amplitude.

The clinical significance is twofold. First, CSD activates the trigeminovascular pain system – its inhibition reduces the very possibility of the aura transitioning into a full-blown pain attack. Second, chronic repetition of CSD leads to plastic changes in the cortex – this is the mechanism of transformation from episodic to chronic migraine. By prophylactically inhibiting CSD, CBD theoretically reduces the risk of this transformation.

Well-known propranolol and topiramate also inhibit CSD, but have drawbacks – cardiovascular contraindications, cognitive function disturbances. CBD fits into this mechanism with a different tolerance profile. The hypothesis is that multi-target action (CB1 + CB2 + TRPV1 + 5-HT1A simultaneously) provides more comprehensive protection than a single pharmacological target of classical drugs. This is a research argument, not clinical evidence – only the results of ongoing RCT studies will resolve this dispute.

How to dose CBD for migraines – prevention and acute attack?

There is no one "universal" scheme, but clinical data and consultant practice are consistent. According to the review by Millar et al. in Frontiers in Pharmacology (2019), therapeutic doses of CBD in chronic pain are usually 20-200 mg daily, with a median of about 50-80 mg. In migraine, a reasonable range is 30-100 mg per day for prophylaxis.

The titration protocol is absolutely essential. Start with 10-20 mg once daily (evening) for 3-5 days. If you tolerate it without drowsiness or gastrointestinal disturbances, add a second dose in the morning. Every 5-7 days, increase by 10 mg until you achieve stable improvement or 100 mg per day. The upper limit in migraines is usually 150 mg – above this, the risk of interactions with CYP3A4 outweighs the benefits.

In an acute attack, act quickly and sublingually. A dose of 20-40 mg of oil under the tongue (hold for 60-90 seconds before swallowing), ideally as early as possible in the prodromal phase or at the onset of the aura. Effect in 15-30 minutes. If pain increases after 45 minutes, you may add NSAIDs (ibuprofen 400 mg or naproxen 500 mg). Avoid combining with triptans without consultation – the common serotonergic pathway theoretically increases the risk of serotonin syndrome, although it is rarely reported in clinical practice.

Converting milligrams to drops – the most common dosing error

5 percent oil contains 50 mg of CBD in 1 ml, which is about 2.5 mg in one drop (standard dropper 20 drops per ml). 10 percent oil contains 100 mg/ml and 5 mg per drop. 15 percent oil – 150 mg/ml and 7.5 mg per drop. A common mistake among beginners is confusing percentage with dosage – "I will take 3 drops of 10 percent oil" gives 15 mg, not 30 mg, as some believe.

For user convenience, we most often recommend 10 percent oils – they cover the widest range of dosing without swallowing large amounts of oil. At a dose of 60 mg daily, 12 drops are sufficient (2 times a day, 6 drops each). 5 percent oils are good for beginners or those with lower body weight. 15-20 percent oils are a solution for patients requiring higher doses – starting from 80 mg per day.

Duration of prevention – when to expect results?

The prevention window is 8-12 weeks of regular use. The first noticeable changes (usually a decrease in the intensity of attacks, not frequency) appear in the 3rd-4th week. Significant reduction in the number of migraine days usually occurs only after 8 weeks. This is the same time frame as for topiramate and propranolol – CBD is not a "miraculous quick fix", but a preventive measure with kinetics comparable to standard medications.

A headache diary is essential. Record: date, start time, duration, intensity on a scale of 0-10, accompanying symptoms (aura, nausea, vomiting), potential triggers (sleep, stress, menstruation, food), current CBD dose, and any acute medications taken. After 8 weeks, compare the month before starting CBD and the last month. If the reduction in migraine days is less than 30 percent – consider increasing the dose or adding THC (medical marijuana under supervision).

How does CBD interact with migraine medications?

CBD inhibits four key liver cytochromes: CYP3A4, CYP2C9, CYP2C19, and CYP1A2. According to Iffland and Grotenhermen, Cannabis and Cannabinoid Research (2017), doses above 40 mg per day can significantly increase the concentration of drugs metabolized by these pathways. In migraine, this means the need to assess specific interactions.

The triptans with the highest risk of interaction with CBD are rizatriptan (metabolized by MAO, but also CYP2D6), almotriptan, and eletriptan (CYP3A4). Safer profiles include sumatriptan (extrahepatic metabolism, primarily excreted by the kidneys) and naratriptan. Practical rule: if you use triptans as needed 2-3 times a month, CBD at a preventive dose of 50-80 mg daily does not generate clinically significant interactions. If you use triptans more than 10 days a month – that is medication-overuse headache, and the entire regimen requires revision by a neurologist.

In migraine prevention, three medications require special attention when combined with CBD: topiramate (levels may increase), propranolol (increased concentration and risk of bradycardia), and amitriptyline (increased concentration and risk of QT prolongation). For all these combinations, titration of CBD is recommended with constant monitoring of symptoms, and for amitriptyline – EKG monitoring at doses of CBD above 50 mg daily.

Anti-CGRP antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) are administered subcutaneously or intravenously and do not undergo hepatic metabolism. This is the safest combination with CBD – the combination provides synergistic anti-migraine effects without significant pharmacokinetic interactions. For patients with chronic migraine resistant to standard prevention, the antibody plus CBD 50-80 mg regimen is becoming an increasingly popular protocol in European centers.

In our consulting practice at u Bucha, the most common mistake among migraine patients is combining high doses of CBD (above 100 mg) with amitriptyline or propranolol without neurological consultation. Side effects – fatigue, bradycardia, dizziness – are often attributed to CBD, while the real culprit is the elevated concentration of the classical medication. Solution: titrate CBD to 40 mg and possibly reduce the dose of classical prevention under medical supervision.

Supporting supplements – magnesium, riboflavin, coenzyme Q10

CBD works synergistically with several well-studied migraine supplements. Magnesium (citrate or glycinate, 400-600 mg daily) has strong evidence of efficacy in the prophylaxis of menstrual migraine and with aura (Maier et al., Nutrients, 2022). Riboflavin (vitamin B2, 400 mg daily) improves mitochondrial function in neurons – a classic recommendation from migraine specialists since the 90s. Coenzyme Q10 (150-300 mg daily) supports the respiratory chain in a complementary way to B2.

Melatonin (3-5 mg in the evening) has evidence of reducing the frequency of attacks in patients with circadian rhythm disorders – a common comorbid element of migraines. CoQ10 and riboflavin can be safely combined with CBD – there are no significant pharmacokinetic interactions. Magnesium does not interact, but may enhance the calming effect after higher doses of CBD.

A rational supplement stack for chronic migraine in 2026 looks as follows: magnesium glycinate 400 mg (in the morning), riboflavin 400 mg (in the morning with a meal), CoQ10 200 mg (with fat for bioavailability), CBD 50-80 mg (divided morning and evening), melatonin 3 mg (in the evening). This regimen addresses four independent pathophysiological pathways of migraine – magnesium deficiency, mitochondrial dysfunction, endocannabinoid deficiency, and circadian rhythm desynchronization. The monthly cost is between 350-500 PLN.

What are the side effects and contraindications of CBD in migraine?

The local safety profile of CBD is one of the best among drugs used in migraine. The report WHO Expert Committee on Drug Dependence (2018) indicates a lack of addictive potential, negligible toxicity, and a low rate of significant adverse effects. In randomized clinical trials, 6-12 percent of participants report mild symptoms – fatigue, diarrhea, changes in appetite.

The most common real issues in migraine are drowsiness (especially at doses above 80 mg in the evening), dry mouth, diarrhea (usually resolves by the 7th-10th day), and transient drops in blood pressure in individuals with baseline hypotension. Less frequently – elevated liver enzymes, usually at doses above 150 mg and typically asymptomatic. In individuals with chronic migraine and coexisting hepatopathy, it is advisable to monitor ALT and AST every 3 months.

Absolute contraindications include severe liver failure, taking warfarin (risk of bleeding due to interaction with CYP2C9), allergy to cannabis (rare), and pregnancy and breastfeeding (lack of long-term safety data). Relative contraindications: simultaneous use of warfarin, clonazepam, valproate in high doses. Pediatric dosing of CBD in migraine in adolescents is not well established – the prevailing opinion is to avoid it in individuals under 16 years of age.

Review Iffland and Grotenhermen, Cannabis and Cannabinoid Research (2017) confirms that the long-term safety of CBD up to 1500 mg per day in adults is good. In migraine, such doses are not necessary – the range of 30-100 mg covers the vast majority of needs. The risk of serious adverse events in this dosing range is minimal and comparable to placebo in most studies.

When to seek urgent help from a neurologist?

CBD is not a substitute for neurological diagnostics. Red flags requiring urgent consultation: the first-ever attack after the age of 50, "the worst headache of my life" with sudden onset (thunderclap), headache with fever and neck stiffness, persistent neurological deficit after pain subsides, change in the character of previously stable migraine, headache occurring strictly in the morning with vomiting. These symptoms suggest pathologies other than migraine (SAH bleeding, meningitis, brain tumor).

A dermatologist cannot replace a neurologist, and a pharmacist from the pharmacy cannot replace a headache specialist. If chronic migraine (more than 15 days with headache per month) or resistant to standard prophylaxis, referral to a headache clinic allows for the use of anti-CGRP antibodies, gepants, and newer protocols that CBD cannot replace.

How much does monthly CBD therapy for migraine cost and is it worth it?

The cost depends on the chosen dose and concentration of the oil. At a dose of 50 mg daily and 10 percent oil (1000 mg CBD in a 10 ml bottle for 200-280 PLN), a month of therapy costs 150-260 PLN. A dose of 100 mg daily doubles this amount. For comparison, monthly therapy with eptinezumab (the latest anti-CGRP antibody) costs 2000-2500 PLN, topiramate 25 PLN, propranolol 10 PLN, amitriptyline 15 PLN monthly. CBD falls within the mid-range price for migraine treatment.

It is worth considering the hidden costs of standard pharmacotherapy. Topiramate requires monitoring of creatinine and body weight, causes weight loss, concentration disturbances (brain fog), and paresthesia. Propranolol controls blood pressure but can cause bradycardia, fatigue, and worsening asthma. Amitriptyline generates weight gain, dryness, constipation, and libido disturbances. The cost of losing professional work for a patient with chronic migraine is estimated at 9000-15000 PLN annually in Polish conditions (data from the Polish Headache Society).

For individuals with chronic migraine resistant to treatment, a combined strategy based on anti-CGRP antibodies plus 50 mg CBD provides the best efficacy-to-tolerance ratio, although the cost is the highest. For episodic migraine (less than 15 days with attacks per month), CBD prophylaxis alone plus possibly triptan as needed is a rational starting point, especially for patients with cardiovascular contraindications to triptans.

5 percent oils (about 70-90 PLN for 10 ml) are a good entry point – allowing for the first 2-3 months of a so-called trial period without a large expense. Once effectiveness is confirmed, migrating to 10-15 percent oils reduces the cost per milligram of CBD by 20-30 percent. For patients with doses above 80 mg daily, 15-20 percent oils are the most cost-effective, although the price entry threshold is higher.

For a broader context of cannabinoid action in the body, it is worth reading our text how CBD and other cannabinoids affect the human body, which explains the mechanisms of the ECS in a simplified way. The guide is also useful on how to take CBD – especially if you are considering oil, vaporization, or capsules.

Does CBD work for menstrual migraines, in men and older individuals?

Menstrual migraines affect 35-51 percent of women of childbearing age and are exceptionally resistant to standard prophylaxis (Maasumi et al., The Journal of Headache and Pain, 2021). The drop in estrogen during the perimenstrual period destabilizes the ECS – precisely when external CBD supplementation may bring the greatest benefit. Practical scheme: increase the CBD dose by 20-30 percent 3 days before menstruation and maintain it for 2 days after.

Migraine in men (about 6 percent of the male population) is less frequently explored in studies, but available data suggest comparable effectiveness of CBD as in women. In this group, chronic migraine with a tension component, work-related stress, and sleep disorders often dominate. CBD at a regimen of 40-60 mg daily combines migraine prevention with stress reduction and improved sleep quality – three benefits in one preparation.

In individuals over 60 years of age, CBD dosing requires caution due to polypharmacy and increased liver sensitivity to interactions. A reasonable start is 10 mg once daily, slowly titrating to 30-40 mg. An additional benefit is the potential neuroprotective effect of CBD, which theoretically may slow age-related changes. Research in this group is limited – hence the recommendation for special medical consultation.

Individuals with migraine and concomitant depression or anxiety constitute a group in which CBD has a unique advantage. A study Shannon et al., The Permanente Journal (2019) showed that 25-75 mg of CBD daily for 3 months reduces anxiety in 79.2 percent of patients. In individuals with migraine and depression, a dose of 40-80 mg provides combined benefits – fewer attacks, less anticipatory anxiety, and improved sleep. More about the impact of CBD on depression and mood in our article does CBD help in treating depression, and about the role of cannabinoids in social phobia and anxiety – in the text on CBD and social phobia.

Chronic migraine and medication overuse headache – special scenarios

Chronic migraine (more than 15 days with headache per month, including at least 8 with migraine features) affects 1-2 percent of the population and requires a more intensive strategy. In this group, CBD at a dose of 80-120 mg as an adjunct to classical prophylaxis (topiramate, propranolol, anti-CGRP antibodies) is rational – a synergistic effect. Expected benefit: reduction of 3-5 migraine days per month after 12 weeks.

Medication overuse headache (MOH) develops in individuals who misuse acute medications – more than 10 days a month of triptans or opioids, more than 15 days of NSAIDs. Treatment requires gradual withdrawal of the medication and initiation of prophylaxis. CBD may help during the detoxification phase – alleviating rebound symptoms, reducing pain and anticipatory anxiety related to fear of severe pain. This application is outside the registered indication, but mechanistically rational.

Among patients with cluster headache – a rarer but dramatically painful type of headache – data on CBD is less abundant but promising. The work of Leroux et al. in The Journal of Headache and Pain (2013) suggested that cannabinoids may interrupt a series of attacks, but further randomized studies are required. In practice, many patients with cluster migraine report benefits from prophylaxis with full-spectrum hemp oil at a dose of 60-80 mg daily.

How to choose a good CBD oil for migraine therapy?

The quality of CBD oil is not an aesthetic issue – it directly affects clinical efficacy. According to the review Bonn-Miller et al., JAMA (2017), 69 percent of CBD products available online in the USA had a discrepancy between declared and actual CBD content greater than 10 percent. In Europe, the situation is better, but quality control remains crucial.

Five criteria for good CBD oil for migraines. First – a certificate of analysis (COA) from an independent laboratory confirming the exact content of CBD, CBG, THC, and absence of contaminants (pesticides, heavy metals, solvents). Second – full spectrum or broad spectrum extract, not isolate. Third – carrier oil MCT, hemp, or olive oil, not palm or mineral oil. Fourth – dark glass bottle to protect from light. Fifth – documented extraction date and expiration date.

In Poland, reliable producers include CannabiGOLD (Polish hemp from Poznań), HemPoland, Essence of Spring, and BioBloom. These brands publish full analytical reports, use CO2 extraction at low temperatures (protecting terpenes), and declare CBD content consistent with the label. Oils from unverified brands for 50 PLN for 10 ml are usually products with contaminants or below the declared concentration.

For migraines, we specifically recommend full-spectrum oils with a predominance of CBD, moderate CBG content (anti-inflammatory), and CBC (supports neurogenesis), trace THC content up to 0.2 percent, and high levels of the terpenes myrcene (relaxing) and beta-caryophyllene (CB2 agonist, anti-inflammatory). Such compositions best fit mechanistically with the pathophysiology of migraine.

Do CBG and CBN support migraine therapy?

CBG (cannabigerol) is the "mother of all cannabinoids" – from it, CBD, THC, and CBC are derived. It has stronger anti-inflammatory effects than CBD and good evidence in neuropathic pain. In migraines, CBG has been studied since 2020 – preliminary data suggest that compositions of 10 percent CBD plus 2 percent CBG may be more effective than pure CBD in reducing vascular tension.

CBN (cannabinol) is formed from the oxidation of THC and has sedative effects, but is not psychoactive. In migraines, CBN is sometimes used for evening prophylaxis – its sedative effect helps patients whose sleep disturbances are a key trigger for attacks. A dose of 5-10 mg of CBN in the evening combined with 30 mg of CBD is a rational scheme for "wake-up" migraines.

Frequently Asked Questions

Does CBD really help with migraines?

Data from 2021-2024 suggest moderate efficacy. The study by Kuhathasan et al. (Journal of Cannabis Research, 2021) showed a significant reduction in pain intensity in 55 percent of participants after using cannabinoids. CBD modulating CB1, CB2, TRPV1, and inhibiting CGRP fits mechanistically with the pathophysiology of migraine. Meta-analyses of medical cannabis confirm its clinical value in chronic migraine.

What dose of CBD should be used for migraine?

The titration scheme is the standard for 2026: starting from 10-20 mg daily, increasing by 10 mg every 5-7 days, aiming for 50-100 mg per day in divided doses. Prophylaxis requires a constant level – 2-3 times a day. In an acute attack, oil under the tongue (sublingually) works in 15-30 minutes, with a dose of 20-40 mg at a time. Consult a specialist if you are taking triptans or medications metabolized by CYP3A4.

How long does it take for CBD to start working on migraines?

In an acute attack, CBD oil under the tongue takes effect in 15-30 minutes – sublingual bioavailability is 13-19 percent according to Millar et al., Frontiers in Pharmacology (2018). Prophylaxis requires 4-8 weeks of regular use. The study by Nicolodi et al. (2017) showed a 40 percent reduction in attack frequency after 3 months of therapy with full-spectrum cannabinoids.

Can CBD be combined with triptans and other migraine medications?

With caution. CBD inhibits cytochromes CYP3A4, CYP2C9, and CYP2C19, which may increase the concentration of rizatriptan, almotriptan, topiramate, and propranolol. Safer combinations are sumatriptan (extrahepatic metabolism) and eptinezumab (anti-CGRP antibody). Before adding CBD to regular migraine therapy, consult dosing with a neurologist, especially at CBD doses above 50 mg daily.

Does CBD help with migraines with aura?

Preliminary data suggest that it does. Aura is associated with a wave of spreading cortical depolarization (CSD), and experimental studies by Greco et al. (Neurotherapeutics, 2020) showed that CBD and CB1 agonists inhibit CSD in animal models. Patients with visual aura often report a shortening of aura duration and less pain intensity with prophylaxis of 30-60 mg of CBD daily.

Is CBD safer than triptans?

It has a more favorable cardiovascular safety profile. Triptans are contraindicated in patients with coronary artery disease, uncontrolled hypertension, and a history of stroke. CBD, according to the report WHO Critical Review Report (2018), shows no potential for addiction and has negligible toxicity. The downside is a slower onset of action. Ideally, CBD serves for prophylaxis, while triptan is for acute attacks.

How much does monthly CBD therapy for migraine cost?

The cost depends on the dose and concentration of the oil. At a dose of 50 mg daily and 10 percent oil (1000 mg CBD in a 10 ml bottle), the monthly expense is 200-350 PLN. In comparison, eptinezumab costs 2000-2500 PLN monthly, and chronic use of triptans at 15 attacks monthly costs 300-600 PLN. CBD falls in the middle of the cost range for migraine treatment.

Does THC plus CBD work better for migraines than CBD alone?

Some studies suggest so. Nicolodi et al. (2017) compared a mixture of 9 percent THC plus 19 percent CBD with amitriptyline and showed comparable efficacy in prophylaxis. Cuttler et al. (Journal of Pain, 2020) noted a 47.3 percent reduction in migraine intensity from the analysis of 1300 sessions, regardless of the THC:CBD profile. In Poland, access to THC requires a prescription, while CBD is available over the counter.

Summary – is it worth including CBD in migraine treatment?

Yes, for episodic migraine with cardiovascular contraindications to triptans, chronic migraine with incomplete response to standard prophylaxis, and menstrual migraine. Data from the Journal of Cannabis Research, Journal of Pain, and Neurotherapeutics consistently show clinically significant reductions in pain intensity (averaging 40-55 percent) and moderate reductions in attack frequency (30-40 percent after 12 weeks). CBD will not replace anti-CGRP antibodies in resistant patients, but it is a rational option for first or second line.

Key takeaways:

• Multifactorial mechanism: CBD modulates CB1, CB2, TRPV1, and 5-HT1A, inhibits CGRP, and stabilizes mast cells.
• Optimal scheme: 50-100 mg daily in 2-3 doses, titration over 8-12 weeks.
• Acute attack: 20-40 mg sublingually, effect in 15-30 minutes.
• Safety: 6-12 percent mild adverse effects, minimal cardiovascular risk.
• Interactions: caution with triptans metabolized by CYP3A4, topiramate, propranolol, amitriptyline.

It is worth reading labels, choosing products with a COA (Certificate of Analysis) confirming the exact content of CBD and trace THC concentration (below 0.2 percent in Poland), and treating therapy as a multi-month process. If you are looking for verified hemp oils in Polish distribution, check the category CBD and CBG oils at ubucha.pl – products with certificates of analysis and full-spectrum formulations from Polish hemp.

For a broader clinical context, we also recommend texts on how endocannabinoids alleviate stress and pain, how CBD and THC relieve pain in oncological patients and how cannabis is used in the treatment of acne and skin inflammatory conditions – pain-relieving and anti-inflammatory mechanisms largely overlap with those used in migraines.

This article is for informational and educational purposes and does not constitute medical advice. Before starting to use cannabis or CBD for therapeutic purposes, consult with a doctor, especially if you are taking other medications, are pregnant, or breastfeeding.

Author: Michał Waluk, Editor of the u Bucha blog. Publication date: September 27, 2025. Last updated: April 23, 2026.